tbuckley/cabot-search huggingface dataset:
Prognostic Impact of neutrophil to lymphocyte ratio (NLR) in patients (pts) with recurrent primary malignant brain tumours (PMBT) in phase I (Ph1) trials: The Royal Marsden (RMH) Experience
Authors: N. Coleman, V. Michalarea, S. Alken, R. Perez Lopez, N. Tunariu, A. Petruckevitch, U. Banerji, J. de Bono, L. Welsh, F. Saran, J. Lopez
Journal: Annals of Oncology (2017)
Immune checkpoint inhibitor (ICPI) efficacy and resistance detected by comprehensive genomic profiling (CGP) in non-small cell lung cancer (NSCLC)
Authors: J.S. Ross, M.E. Goldberg, L.A. Albacker, L.M. Gay, V. Agarwala, J.A. Elvin, J-A. Vergilio, J. Suh, S. Ramkissoon, E. Severson, S. Daniel, S.M. Ali, A.B. Schrock, G.M. Frampton, D. Fabrizio, V.A. Miller, G. Singal, A. Abernethy, P.J. Stephens
Journal: Annals of Oncology (2017)
Health-related quality of life (HRQL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (CBZ) in a prospective observational study (CAPRISTANA)
Authors: A. Pichler, G. Barnes, J. Katolicka, H. Korunkova, A. Tomova, M. Ghosn, F. El Karak, I. Koroleva, J. Makdessi, A. Ozatilgan, S. Hitier, J. Carles
Journal: Annals of Oncology (2017)
GW28-e0183 H2O2-loaded Acoustic Phase-Change Nanoparticles Enhancing Coronary Micro-Circulation Thrombolysis: An In Vitro Study by Low Intensity Focused Ultrasound Irradiation
Authors: Nan Jiang, Bo Hu, Qing Zhou, Jinling Chen, Sheng Cao, Ruiqiang Guo
Journal: Journal of the American College of Cardiology (2017)
The prognostic role of neutrophil-to-lymphocyte ratio (NLR) in patients with metastatic germ cell tumors
Authors: D. Ribnikar, P.L. Bedard, R.J. Hamilton, M. Jewett, P. Warde, P. Chung, L. Anson Cartwright, A. Templeton, E. Amir, A.R. Hansen, J. Lewin
Journal: Annals of Oncology (2017)
Correction to: ReMixT: clone-specific genomic structure estimation in cancer
Authors: Andrew W. McPherson, Andrew Roth, Gavin Ha, Cedric Chauve, Adi Steif, Camila P. E. de Souza, Peter Eirew, Alexandre Bouchard-Côté, Sam Aparicio, S. Cenk Sahinalp, Sohrab P. Shah
Journal: Genome biology (2017)

implies that at least one segment end is left disconnected (Fig. 2 d).
Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Post-progression outcomes from the phase 2 IMvigor210 study
Authors: A. Necchi, R.W. Joseph, Y. Loriot, J. Hoffman-Censits, J.L. Perez Gracia, D.P. Petrylak, Q. Zhu, B. Ding, C. Kaiser, J.E. Rosenberg
Journal: Annals of Oncology (2017)
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology–Friends of Cancer Research Brain Metastases Working Group
Authors: Nancy U. Lin, Tatiana Prowell, Antoinette R. Tan, Marina Kozak, Oliver Rosen, Laleh Amiri-Kordestani, Julia White, Joohee Sul, Louise Perkins, Katherine Beal, Richard Gaynor, Edward S. Kim
Journal: Journal of Clinical Oncology (2017)

Purpose Broadening trial eligibility to improve accrual and access and to better reflect intended-to-treat populations has been recognized as a priority. Historically, patients with brain metastases have been understudied, because of restrictive eligibility across all phases of clinical trials. Methods In 2016, after a literature search and series of teleconferences, a multistakeholder workshop was convened. Our working group focused on developing consensus recommendations regarding the inclusion of patients with brain metastases in clinical trials, as part of a broader effort that encompassed minimum age, HIV status, and organ dysfunction. The working group attempted to balance the needs of protecting patient safety, facilitating access to investigational therapies, and ensuring trial integrity. On the basis of input at the workshop, guidelines were further refined and finalized. Results The working group identified three key populations: those with treated/stable brain metastases, defined as patients who have received prior therapy for their brain metastases and whose CNS disease is radiographically stable at study entry; those with active brain metastases, defined as new and/or progressive brain metastases at the time of study entry; and those with leptomeningeal disease. In most circumstances, the working group encourages the inclusion of patients with treated/stable brain metastases in clinical trials. A framework of key considerations for patients with active brain metastases was developed. For patients with leptomeningeal disease, inclusion of a separate cohort in both early-phase and later-phase trials is recommended, if CNS activity is anticipated and when relevant to the specific disease type. Conclusion Expanding eligibility to be more inclusive of patients with brain metastasis is justified in many cases and may speed the development of effective therapies in this area of high clinical need.
Phase II study of docetaxel, carboplatin and trastuzumab (THC) in patients with locally advanced breast cancer
Authors: L. Y. Dirix, A. Prové, C. Sweldens, P. Van Dam, P. Vermeulen, I. Benoy
Journal: Journal of Clinical Oncology (2007)

1062 Background: Preclinical and clinical data suggest that docetaxel, trastuzumab and platinum compounds act synergistically. Studies in the metastatic disease are conflicting. In this phase II study the activity of this regimen was assessed and correlated with changes in circulating biomarkers. Methods: Patients with locally advanced, FISH+ HER2 amplified, breast cancer were treated in this protocol with TCH as initial neo-adjuvant treatment. Patients received Docetaxel 75 mg/sqm, carboplatinum AUC 6mg/mL.min and trastuzumab 6 mg/kg (with a loading dose in cycle 1). Six cycles were intended provided no progression occured. No prophylactic G-CSF or antibiotics were administered. Measurement of circulating ECD HER2, CTC (RT-PCR mammaglobin and CK-19), and total plasma DNA was performed prior to the start of therapy, after cycle 1 and after 3 and 6 cycles. A cardiac MUGA exam was performed every three cycles. All patients were intented to undego mastectomy and axillary clearance after the end of chemotherapy. Results: 40 patients have been treated with a median age of 56 year. No patient suffered from progression of disease while on THC. All patients received 6 cycles, 4 patients received respectively 7, 7, 8 and 9 cycles. In total 247 cycles were administered. No cases of CHF were observed. 5 patients suffered from a asymptomatic decline &gt; 10% in LVEF. A clinical CR and PR was obtained in 32 (80%). A pathological CR both in breast axilla was obtained in 16/39 (41%). Tumor response was predicted by changes in both CTC and ECD HER-2. Conclusions: THC was confirmed to be a very active and safe regimen in patients with HER-2 amplified breast cancer. Changes in biomarkers rapidly predicted response. No significant financial relationships to disclose.
Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): Updated results of IDEA (International Duration Evaluation of Adjuvant chemotherapy)
Authors: A. Grothey, A. Sobrero, J.A. Meyerhardt, T. Yoshino, J. Paul, J. Taieb, I. Souglakos, R. Kerr, R. Labianca, A.F. Shields, F. Bonnetain, T. Yamanaka, I. Boukovinas, Q. Shi, J.P. Meyers, D. Niedzwiecki, V. Torri, D.J. Sargent, T. André, T. Iveson
Journal: Annals of Oncology (2017)
Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer
Authors: M. Ilié, E. Szafer-Glusman, V. Hofman, E. Chamorey, S. Lalvée, E. Selva, S. Leroy, C.-H. Marquette, M. Kowanetz, P. Hedge, E. Punnoose, P. Hofman
Journal: Annals of Oncology (2017)

BackgroundExpression of PD-L1 in tumor cells and tumor-infiltrating immune cells has been associated with improved efficacy to anti-PD-1/PD-L1 inhibitors in patients with advanced-stage non-small-cell lung cancer (NSCLC) and emerged as a potential biomarker for the selection of patients to cancer immunotherapies. We investigated the utility of circulating tumor cells (CTCs) and circulating white blood cells (WBCs) as a noninvasive method to evaluate PD-L1 status in advanced NSCLC patients.Patients and methodsCTCs and circulating WBCs were enriched from peripheral blood samples (ISET® platform; Rarecells) from 106 NSCLC patients. PD-L1 expression on ISET filters and matched-tumor tissue was evaluated by automated immunostaining (SP142 antibody; Ventana), and quantified in tumor cells and WBCs.ResultsCTCs were detected in 80 (75%) patients, with levels ranging from 2 to 256 CTCs/4 ml, and median of 60 CTCs/4 ml. Among 71 evaluable samples with matched-tissue and CTCs, 6 patients (8%) showed ≥1 PD-L1-positive CTCs and 11 patients (15%) showed ≥1% PD-L1-positive tumor cells in tumor tissue with 93% concordance between tissue and CTCs (sensitivity = 55%; specificity = 100%). From 74 samples with matched-tissue and circulating WBCs, 40 patients (54%) showed ≥1% PD-L1-positive immune infiltrates in tumor tissue and 39 patients (53%) showed ≥1% PD-L1 positive in circulating WBCs, with 80% concordance between blood and tissue (sensitivity = 82%; specificity = 79%). We found a trend for worse survival in patients receiving first-line cisplatin-based chemotherapy treatments, whose tumors express PD-L1 in CTCs or immune cells (progression-free and overall survival), similar to the effects of PD-L1 expression in matched-patient tumors.ConclusionsThese results demonstrated that PD-L1 status in CTCs and circulating WBCs correlate with PD-L1 status in tumor tissue, revealing the potential of CTCs assessment as a noninvasive real-time biopsy to evaluate PD-L1 expression in patients with advanced-stage NSCLC.
Efficacy and mechanism of dendritic cell-based immunotherapy with CpG and IFN-alpha-expressing tumor cells for murine colorectal cancer
Authors: Hiroyoshi Doi, Kazumasa Hiroishi, Ayako Hiraide, Junichi Eguchi, Shigeaki Ishii, Takuya Matsumura, Masashi Sakaki, Michio Imawari
Journal: Cancer Research (2008)

2869   Dendritic cells (DCs) are known as professional antigen-presenting cells (APCs) characterized by their potent ability to elicit immune responses to foreign antigens. Interferon (IFN) α has many biologic effects including enhancement of the proliferation of type I helper T cells. We have previously demonstrated the synergistic effects of CpG-oligonucleotide (ODN) and interferon (IFN) α on DC maturation in vitro. In this study, we evaluated the anti-tumor effects of DCs pre-incubated with IFN-α gene-overexpressing murine colorectal cancer MC38 cells (MC38-IFNα) and CpG-ODN in a poorly immunogeneic murine cancer system. When DCs pre-incubated with MC38-IFNα and CpG-ODN were inoculated subcutaneously into mice bearing MC38 wild-type tumors, the outgrowth of the established parental tumors was significantly suppressed compared with that following administration of DCs with MC38-IFNα (p=0.008). All mice injected with DCs pre-incubated with MC38-IFNα and CpG-ODN rejected a subsequent parental tumor challenge. Immunohistochemical and flow cytometrical analyses showed that CD4+ cells, CD8+ cells, and NK1.1+ cells markedly infiltrated the established tumors of mice treated with DCs pre-incubated with MC38-IFNα and CpG-ODN. From the results in immune-cell-depleted mice, CD4+ cells and asialo-GM1+ cells seemed to contribute to the anti-tumor effects induced by the combination DC therapy. Furthermore, non-specific as well as tumor-specific cytolysis was detected when splenocytes of mice inoculated with DCs pre-incubated with MC38-IFNα and CpG-ODN were used as effector cells. Using an IL-12-neutralizing antibody, it was suggested that IL-12 stimulates natural killer cells and plays a partial role in the anti-tumor effects induced by DCs incubated with CpG-ODN and IFN-α. Since DC-based immunotherapy with CpG-ODN and IFN-α-expressing tumor cells induces a potent anti-tumor immune response, it should be considered for clinical application.
The ethical landscape of patients with leukemia: Common issues and best practices.
Authors: Jeffrey S. Farroni, Philip A. Thompson, Jorge E. Cortes, Colleen M. Gallagher
Journal: Journal of Clinical Oncology (2015)

e18085 Background: Leukemia represents a complex spectrum of malignancies, involving numerous treatment options and substantial symptom burden for patients. Ethical dilemmas may arise which challenge a physician’s clinical management and the patient’s goals of care. Understanding the ethical landscape in the context of leukemia treatment will better prepare the practitioner with best ethical practices for optimized patient care. Methods: In this retrospective review, we examined 312 formal ethics consultations requested on patients with a leukemia diagnosis over a period of twenty years. We described the most common clinical case types and underlying issues observed by ethics consultants on the Leukemia service. Results: The four most common issues were deciding on the level of appropriate treatment (n = 161, 23.7%), determining the surrogate decision-maker (n = 112, 16.5%), the futility of further aggressive interventions (n = 86, 12.7%) and patient non-adherence to the clinical plan (n = 59, 8.7%). The predominant underlying issues were insufficient psychosocial support (n = 195, 31.4%), disagreements between parties most notably between the medical team and patient caregivers (n = 143, 23.0%), communication barriers (n = 96, 15.5%) and consult requestor support (n = 64, 10.3%). Support in this instance ranges from validation of difficult decisions that have already been made to coping. Psychosocial issues include complex and/or conflicting family dynamics, spiritual issues and cultural barriers to care. Conclusions: Leukemia treatment poses many complex moral and ethical dilemmas ranging from the limits of clinical intervention, managing patient expectations, meeting patient goals, coping with suffering, etc. Illuminating these issues provides areas of focus for the practitioner to refine their practice and inform educational initiatives. The integration of the clinical ethics service into the multidisciplinary team is a mechanism to foster a preventative ethics model and mitigate potential dilemmas.
Characteristics and prognosis of gastrointestinal stromal tumor in the pre-imatinib era: An analysis based on the Kinki GIST registry in Japan
Authors: T. Hashimoto, T. Takahashi, Y. Kurokawa, J. Fujita, S. Hirota, T. Nishida, T. Tsujinaka
Journal: Annals of Oncology (2017)
Preoperative chemoradiotherapy after induction FOLFIRINOX improve R0 resection margins rate and histological response in patients secondary resected in borderline or locally advanced pancreatic adenocarcinoma
Authors: D. Pietrasz, O. Turrini, V. Vendrely, C. Laurent, E. Terrebonne, O. Hentic Dhome, A. Sauvanet, J-M. Simon, R. Coriat, F. Portales, B. Le Roy, A-L. Pointet, L. Marthey, N. Regenet, D. Goere, P. Artru, J-C. Vaillant, J-R. Delpero, J-B. Bachet, A. Sa Cunha
Journal: Annals of Oncology (2017)
Adjuvant GEMOX for biliary tract cancer: Updated relapse-free survival and first overall survival results of the randomized PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial
Authors: J. Edeline, F. Bonnetain, J-M. Phelip, J. Watelet, P. Hammel, J-P. Joly, M. Benabdelghani, L. Fartoux, K. Bouhier-Leporrier, J-L. Jouve, R. Faroux, V. Guerin-Meyer, E. Assenat, J-F. Seitz, D. Malka, C. Louvet, A. Bertaut, B. Juzyna, T. Stanbury, E. Boucher
Journal: Annals of Oncology (2017)
Epidemiology of keratinocyte carcinomas after organ transplantation
Authors: M.M. Madeleine, N.S. Patel, E.I. Plasmeijer, E.A. Engels, J.N. Bouwes Bavinck, A.E. Toland, A.C. Green
Journal: British Journal of Dermatology (2017)

Keratinocyte carcinoma (KC) is the most common type of cancer among white populations, but it is even more common among solid organ transplant recipients (OTRs). The most frequent histological type of KC among OTRs is cutaneous squamous cell carcinoma (cSCC), followed by basal cell carcinoma, although the reverse is seen in the general population. Metastatic cSCCs are more frequent, and mortality is increased compared with immunocompetent populations. There is strong evidence that the risk of KC among OTRs rises with increasing time after transplantation and older age at transplantation, and that KC is enhanced in those with sun‐damaged skin. This evidence suggests that accelerated accumulation of genetic damage from several sources leads to excess KC in OTRs. We describe international variation in KC and focus on trends in immunosuppressive regimens, the role of ultraviolet susceptibility and exposure, and the contribution of genetics to tumour development. Further epidemiological studies are needed to address gaps in our understanding of the mediation of excess KC by immunosuppressive drugs, viral infection, genetic susceptibility, timing of relevant ultraviolet exposure or some combination of these factors.
Comparison of circulating tumor DNA (ctDNA) profile in metastatic urothelial carcinoma (mUC) derived from the upper tract (UT) and lower tract (LT)
Authors: N. Agarwal, S.K. Pal, G. Sonpavde, L.A. Kiedrowski, R.J. Nagy, K. Banks, R. Lanman, P. Grivas
Journal: Annals of Oncology (2017)
Epidémie d'hépatite A en Italie dans les Pouilles, 1996
Authors: P Malfait, P L Lopalco, S Salmaso, C A Germinario, G Salamina, M Quarto, S Barbuti, R Cipriani, A Mundo, G Pesole
Journal: Eurosurveillance (1996)

Dans la region des Pouilles situee dans le sud-est de l'Italie (population : 4 millions), le nombre de declarations d'infection par le virus de l'hepatite A (VHA) augmente tous les deux ans. En 1992, une epidemie tres importante a ete observee mais aucune investigation epidemiologique n'avait ete realisee. La plupart des cas sont declares en debut d'annee (figure 1). Fin 1995, la region des Pouilles a integre le projet national d'informatisation du systeme de surveillance des maladies infectieuses (Sistema Informatizzato sulle Malattie Infettive, SIMI).
Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation
Authors: William H. Herman, Qing Pan, Sharon L. Edelstein, Kieren J. Mather, Leigh Perreault, Elizabeth Barrett-Connor, Dana M. Dabelea, Edward Horton, Steven E. Kahn, William C. Knowler, Carlos Lorenzo, Xavier Pi-Sunyer, Elizabeth Venditti, Wen Ye
Journal: Diabetes Care (2017)

OBJECTIVE Both lifestyle and metformin interventions can delay or prevent progression to type 2 diabetes mellitus (DM) in people with impaired glucose regulation, but there is considerable interindividual variation in the likelihood of receiving benefit. Understanding an individual’s 3-year risk of progressing to DM and regressing to normal glucose regulation (NGR) might facilitate benefit-based tailored treatment. RESEARCH DESIGN AND METHODS We used the values of 19 clinical variables measured at the Diabetes Prevention Program (DPP) baseline evaluation and Cox proportional hazards models to assess the 3-year risk of progression to DM and regression to NGR separately for DPP lifestyle, metformin, and placebo participants who were adherent to the interventions. Lifestyle participants who lost ≥5% of their initial body weight at 6 months and metformin and placebo participants who reported taking ≥80% of their prescribed medication at the 6-month follow-up were defined as adherent. RESULTS Eleven of 19 clinical variables measured at baseline predicted progression to DM, and 6 of 19 predicted regression to NGR. Compared with adherent placebo participants at lowest risk of developing diabetes, participants at lowest risk of developing diabetes who adhered to a lifestyle intervention had an 8% absolute risk reduction (ARR) of developing diabetes and a 35% greater absolute likelihood of reverting to NGR. Participants at lowest risk of developing diabetes who adhered to a metformin intervention had no reduction in their risk of developing diabetes and a 17% greater absolute likelihood of reverting to NGR. Participants at highest risk of developing DM who adhered to a lifestyle intervention had a 39% ARR of developing diabetes and a 24% greater absolute likelihood of reverting to NGR, whereas those who adhered to the metformin intervention had a 25% ARR of developing diabetes and an 11% greater absolute likelihood of reverting to NGR. CONCLUSIONS Unlike our previous analyses that sought to explain population risk, these analyses evaluate individual risk. The models can be used by overweight and obese adults with fasting hyperglycemia and impaired glucose tolerance to facilitate personalized decision-making by allowing them to explicitly weigh the benefits and feasibility of the lifestyle and metformin interventions.
Feasibility and barriers to optimal oncological treatment in solid organ transplant patients with de novo cancer
Authors: B. Rousseau, A. Jobard, C. Duvoux, C. Neuzillet, P. Compagnon, D. Azoulay, A. de la Taille, L. Salomon, I. Cholley, M. Matignon, P. Grimbert, C. Tournigand
Journal: Annals of Oncology (2017)
Transarterial chemoembolization with or without microwave ablation in the treatment of intermediate (BCLC B) hepatocellular carcinoma.
Authors: Feng Shi, Shanshan Lian, Peihong Wu, Lujun Shen
Journal: Journal of Clinical Oncology (2017)

e15635 Background: Transarterial chemoembolization (TACE) is currently the first-line treatment for patients with intermediate (BCLC stage B) hepatocellular carcinoma (HCC). However, the prognosis of patients with intermediate HCC remains unsatisfactory, because TACE was limited by its lack of ability to achieve complete tumor necrosis. In this study, we retrospectively compare the outcome of TACE with or without microwave ablation (MWA) in the treatment of intermediate HCC. Methods: Included in this study were 140 patients with intermediate stage HCC who underwent initial TACE and were potentially amendable for MWA (the sum of the size of the largest tumor in centimeters and the number of tumors should be no more than nine; and a total tumor diameter ≤11 cm) between January 2005 and February 2015. 75 patients were treated with following MWA (TACE-MWA), and the remaining 65 patients were treated with TACE alone. Cumulative overall survival (OS) and progression-free survival (PFS) rates were compared. Results: The respective 1-, 3-, and 5-year OS rates were 80%, 30%, and 20% in the TACE group; and 96%, 69%, and 48% in the TACE-MWA group (Fig. 2). The OS was statistically significantly better in the TACE-MWA group compared with the TACE group (P &lt; 0.001). The respective 1-, 3-, and 5-year PFS rates were 53%, 13%, and 0% in the TACE group; and 59%, 27%, and 17% in the TACE-MWA group (Fig. 3B). PFS rates between the two groups did not differ significantly (P = 0.069). Conclusions: MWA following initial TACE prolongs OS and PFS of patients with potentially amendable intermediate HCC.
A randomized phase III trial comparing 4 courses and 8 courses of S-1 adjuvant chemotherapy for p-stage II gastric cancer: JCOG1104 (OPAS-1)
Authors: T. Yoshikawa, M. Terashima, J. Mizusawa, S. Nunobe, Y. Nishida, M. Kaji, N. Fukushima, S. Hato, Y. Choda, H. Yabusaki, K. Yoshida, S. Ito, A. Takeno, T. Yasuda, Y. Kawachi, H. Katayama, H. Fukuda, N. Boku, T. Sano, M. Sasako
Journal: Annals of Oncology (2017)
Evolução recente das infecções meningocócicas na Europa
Authors: B Hubert, D A Caugant
Journal: Eurosurveillance (1997)

Poucas infeccoes provocam tanta consternacao social como a que se verifica sempre que ocorre uma infeccao meningococica numa comunidade. A capacidade da Neisseria meningitidis para matar uma crianca saudavel, em poucas horas, e uma das razoes de tal angustia. E tambem verdade que as medidas preventivas disponiveis contra esta doenca sao limitadas e baseiam-se, fundamentalmente, no diagnostico e tratamento precoces, bem como na prevencao de casos secundarios.